NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

$6.58
-0.30 (-4.36%)
(As of 04/24/2024 ET)
Today's Range
$6.53
$6.92
50-Day Range
$6.58
$17.96
52-Week Range
$6.42
$21.42
Volume
1.00 million shs
Average Volume
1.56 million shs
Market Capitalization
$550.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00

Verve Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
401.5% Upside
$33.00 Price Target
Short Interest
Bearish
28.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Verve Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$12,475 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.92) to ($2.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.68 out of 5 stars

Medical Sector

419th out of 907 stocks

Pharmaceutical Preparations Industry

188th out of 420 stocks

VERV stock logo

About Verve Therapeutics Stock (NASDAQ:VERV)

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Stock Price History

VERV Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Verve Therapeutics: An Update On Human CRISPR
See More Headlines
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
255
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$55.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+401.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-200,070,000.00
Net Margins
-1,701.70%
Pretax Margin
-1,699.21%

Debt

Sales & Book Value

Annual Sales
$11.76 million
Book Value
$7.31 per share

Miscellaneous

Free Float
65,725,000
Market Cap
$550.22 million
Optionable
Optionable
Beta
1.70
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Burt A. Adelman M.D. (Age 72)
    Co-Founder & Independent Chairman of the Board
    Comp: $87.55k
  • Dr. Sekar Kathiresan M.D. (Age 52)
    Co-Founder, CEO & Director
    Comp: $899.55k
  • Mr. Andrew D. Ashe J.D.Mr. Andrew D. Ashe J.D. (Age 57)
    President, COO & General Counsel
    Comp: $703.85k
  • Dr. Andrew Bellinger M.D. (Age 45)
    Ph.D., Chief Scientific Officer
    Comp: $703.85k
  • Dr. Kiran Musunuru M.D.
    M.P.H., Ph.D., Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Anthony Philippakis M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. Barry S. Ticho FACC (Age 63)
    M.D., Ph.D., Co-Founder
  • Mr. Issi Rozen M.B.A.
    Co-Founder & Strategic Advisor
  • Ms. Allison Dorval (Age 48)
    CFO & Principal Accounting Officer
    Comp: $260.93k

VERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings
or view top-rated stocks.

What is Verve Therapeutics' stock price target for 2024?

8 equities research analysts have issued 12-month price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they anticipate the company's stock price to reach $33.00 in the next year. This suggests a possible upside of 401.5% from the stock's current price.
View analysts price targets for VERV
or view top-rated stocks among Wall Street analysts.

How have VERV shares performed in 2024?

Verve Therapeutics' stock was trading at $13.94 on January 1st, 2024. Since then, VERV shares have decreased by 52.8% and is now trading at $6.58.
View the best growth stocks for 2024 here
.

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VERV earnings forecast
.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.14. The business earned $5.14 million during the quarter, compared to analysts' expectations of $3.95 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 39.33% and a negative net margin of 1,701.70%.

What ETFs hold Verve Therapeutics' stock?
When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.10%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends
.

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERV) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners